Indication · Cardiology
Stroke prevention in atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
52
Cleared or approved since 2000
PMA and De Novo
6
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
29
159 device trials in all
Devices
5 devices via PMA. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Watchman Left Atrial Appendage (Laa) Closure Technology
Boston Scientific Corp · PMA · System, Appendage Closure, Left Atrial · newest 2026 · 8 decisions
4 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Elite AF IDE Trial (Elite AF)Recruiting
Boston Scientific CorporationPublic (BSX)
NCT07287436 · 400 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2028
Device: WATCHMAN Elite LAAC Device · For: Atrial Fibrillation (AF); Stroke
Sites: Jonesboro, Arkansas; Santa Monica, California; Rochester, Minnesota · 5 sites in all
158 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on left atrial appendage across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.